文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

群体药代动力学软件对万古霉素稳态谷浓度预测性能的评价

[Predictive performance of population pharmacokinetic software on vancomycin steady-state trough concentration].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论JPKD-vancomycin软件对调整后方案稳态谷浓度预测优于初始方案,女性、低万古霉素清除率及术后患者预测准确性下降。

该研究纳入2013年7月至2018年12月南京医科大学附属苏州医院接受万古霉素治疗并做治疗药物监测的310例患者,共收集467个稳态谷浓度(初始方案310个、调整方案157个)。以权重残差(WRES)评价JPKD-vancomycin软件的预测性能,结果显示调整方案WRES显著低于初始方案[14.84(6.05,22.89)% vs. 20.41(11.06,45.76)%,P<0.01],WRES<30%的比例显著升高[82.80%(130/157)vs. 63.87%(198/310),P<0.01]。多因素Logistic回归显示女性(OR=0.449,95%CI 0.205-0.986,P=0.046)、低万古霉素清除率(OR<0.001,95%CI 0.000-0.081,P=0.015)及术后患者(OR=2.493,95%CI 1.455-4.272,P=0.001)为预测不准确的独立危险因素。当万古霉素清除率低于0.065 L×h-1×kg-1时,软件预测性能下降。

要点

  • 调整方案稳态谷浓度的WRES为14.84(6.05,22.89)%,低于初始方案的20.41(11.06,45.76)%(P<0.01),调整方案WRES<30%的比例为82.80%(130/157),高于初始方案的63.87%(198/310)(P<0.01)。
  • 女性(OR=0.449,95%CI 0.205-0.986,P=0.046)和低万古霉素清除率(OR<0.001,95%CI 0.000-0.081,P=0.015)是JPKD-vancomycin软件预测不准确的独立危险因素。
  • 术后患者是JPKD-vancomycin软件预测不准确的独立危险因素(OR=2.493,95%CI 1.455-4.272,P=0.001)。
  • 万古霉素清除率低于0.065 L×h-1×kg-1时,JPKD-vancomycin软件预测万古霉素稳态谷浓度的性能下降。
  • 万古霉素清除率评估JPKD-vancomycin软件预测准确性的ROC曲线下面积为0.571,敏感度56.3%,特异度57.1%。

适用人群与场景

  • 2013年7月至2018年12月南京医科大学附属苏州医院收治的接受万古霉素治疗并接受治疗药物监测的患者。

诊断标准与关键阈值

  • 稳态谷浓度于首次给药后48小时及下次给药前0.5小时测定。
  • 稳态谷浓度不在10-20 mg/L时调整给药方案,调整后48小时再次测定稳态谷浓度。
  • 以预测稳态谷浓度(Cpre)与实测稳态谷浓度(Creal)之间的权重残差(WRES)评价预测能力,WRES<30%为准确预测组,WRES≥30%为不准确预测组。

处置流程与药物剂量

  • 所有患者按万古霉素用药指南设计经验性万古霉素方案(初始方案)。
  • 先用经典药代动力学软件Vancomycin Calculator计算初始方案,再用JPKD-vancomycin软件预测稳态谷浓度。
  • 用JPKD-vancomycin软件调整万古霉素给药方案并预测调整方案的稳态谷浓度。

研究设计与关键结果

  • 共纳入310例患者,收集467个万古霉素稳态谷浓度,其中初始方案310个、调整方案157个。
  • 调整方案WRES为14.84(6.05,22.89)%,低于初始方案的20.41(11.06,45.76)%(P<0.01)。
  • 调整方案WRES<30%的比例为82.80%(130/157),高于初始方案的63.87%(198/310)(P<0.01)。
  • 准确预测组198个浓度,不准确预测组112个浓度。
  • 单因素Logistic回归显示女性(OR=0.466,95%CI 0.290-0.746,P=0.002)、低体重(OR=0.974,95%CI 0.953-0.996,P=0.022)、矮身高(OR=0.963,95%CI 0.935-0.992,P=0.014)、低万古霉素清除率(OR<0.001,95%CI 0.000-0.231,P=0.023)及术后患者(OR=1.695,95%CI 1.063-2.702,P=0.027)与预测性能相关。
  • 多因素Logistic回归显示女性(OR=0.449,95%CI 0.205-0.986,P=0.046)、低万古霉素清除率(OR<0.001,95%CI 0.000-0.081,P=0.015)及术后患者(OR=2.493,95%CI 1.455-4.272,P=0.001)为预测不准确的独立危险因素。
  • 万古霉素清除率评估预测准确性的ROC曲线下面积为0.571,敏感度56.3%,特异度57.1%。
  • 万古霉素清除率低于0.065 L×h-1×kg-1时,JPKD-vancomycin软件预测性能下降。

证据类型、等级与局限

  • 研究类型:基于医院患者临床数据的药代动力学软件预测性能评价研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为JPKD-vancomycin软件对调整方案万古霉素稳态谷浓度的预测性能优于初始方案。
  • 作者认为患者为女性、万古霉素清除率低及术后患者时,JPKD-vancomycin软件预测性能较差。
  • 作者认为万古霉素清除率低于0.065 L×h-1×kg-1时,JPKD-vancomycin软件预测性能下降。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To estimate the predictive performance of the population pharmacokinetics software JPKD-vancomycin on predicting the vancomycin steady-state trough concentration, and to analyze the related factors affecting the predictive performance.

METHODS: The clinical data of patients who were treated with vancomycin and received therapeutic drug monitoring (TDM) admitted to Suzhou Hospital Affiliated to Nanjing Medical University from July 2013 to December 2018 were enrolled. All patients were designed an empirical vancomycin regimen (initial regimen) according to vancomycin medication guidelines. Steady-state trough concentrations of vancomycin were determined at 48 hours after the first dose and 0.5 hour before the next dose. Dosage regimen was adjusted when steady-state trough concentration was not in 10-20 mg/L (adjustment regimen), and then the steady-state trough concentration was determined again 48 hours after adjustment. First, the JPKD-vancomycin software was used to calculate the initial regimen and predict the steady-state trough concentration according to the results calculated by classic pharmacokinetic software Vancomycin Calculator. Second, the JPKD-vancomycin software was used to adjust the vancomycin dosage regime and predict the steady-state trough concentration of adjustment regimen. The weight residual (WRES) between the predicted steady-state trough concentration (Cpre) and the measured steady-state trough concentration (Creal) was used to evaluate the ability of the JPKD-vancomycin software for predicting the vancomycin steady-state trough concentration. The TDM results of initial regimen were divided into accurate prediction group (WRES < 30%) and the inaccurate prediction group (WRES ≥ 30%) according to the WRES value. Patient and disease characteristics including gender, age, weight, height, the length of hospital stay, comorbidities, vasoactive agent, mechanical ventilation, smoking history, postoperative, obstetric patients, trauma, laboratory indicators, vancomycin therapy and TDM results were collected from electronic medical records. Univariate and multivariate Logistic regression analysis was used to screen the related factors that influence the predictive performance of JPKD-vancomycin software, and the receiver operating characteristic (ROC) curve was drawn to evaluate its predictive value.

RESULTS: A total of 310 patients were enrolled, and 467 steady-state trough concentrations of vancomycin were collected, including 310 concentrations of initial regimen and 157 concentrations of adjustment regimen. Compared with the initial regimen, the WRES of adjusted regimen was significantly reduced [14.84 (6.05,22.89)% vs. 20.41 (11.06,45.76)%, P < 0.01], and the proportion of WRES < 30% increased significantly [82.80% (130/157) vs. 63.87% (198/310), P < 0.01]. These results indicated that JPKD-vancomycin software had a better accuracy prediction for steady-state trough concentration of the adjusted regimen than the initial regimen. There were 198 concentrations in the accurate prediction group and 112 in the inaccurate prediction group. Univariate Logistic regression analysis showed that women [odds ratio (OR) = 0.466, 95% confidence interval (95%CI) was 0.290-0.746, P = 0.002], low body weight (OR = 0.974, 95%CI was 0.953-0.996, P = 0.022), short height (OR = 0.963, 95%CI was 0.935-0.992, P = 0.014), low vancomycin clearance (CLVan; OR < 0.001, 95%CI was 0.000-0.231, P = 0.023) and postoperative patients (OR = 1.695, 95%CI was 1.063-2.702, P = 0.027) were related factors affecting the predictive performance of JPKD-vancomycin software. Multivariate Logistic regression analysis indicated that women (OR = 0.449, 95%CI was 0.205-0.986, P = 0.046), low CLVan (OR < 0.001, 95%CI was 0.000-0.081, P = 0.015) and postoperative patients (OR = 2.493, 95%CI was 1.455-4.272, P = 0.001) were independent risk factors for inaccurate prediction of JPKD-vancomycin software. The ROC analysis indicated that the area under ROC curve (AUC) of the CLVan for evaluating the accuracy of JPKD-vancomycin software in predicting vancomycin steady-state trough concentration was 0.571, the sensitivity was 56.3%, and the specificity was 57.1%. The predictive performance of JPKD-vancomycin software was decreased when CLVan was lower than 0.065 L×h-1×kg-1.

CONCLUSIONS: JPKD-vancomycin software had a better predictive performance for the vancomycin steady-state trough concentrations of adjustment regimen than initial regimen. JPKD-vancomycin software had a poor predictive performance when the patient was female, having low CLVan, and was postoperative. The predictive performance of JPKD-vancomycin software was decreased when CLVan was lower than 0.065 L×h-1×kg-1.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Xue S, Lu H, Tang L, et al. [Predictive performance of population pharmacokinetic software on vancomycin steady-state trough concentration]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32148231. doi:10.3760/cma.j.cn121430-20190814-00009

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。